EUVIMEDEUVIMED entdecken
Crossref

Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis

Mary Nantongo iD, David C Nguyen iD, Christopher R Bethel, Magdalena A Taracila, Qing Li, Khalid M Dousa, Eunjeong Shin, Sebastian G Kurz, Liem Nguyen, Barry N Kreiswirth, W Henry Boom, Mark S Plummer und 1 weitere

ACS Infectious Diseases · 2024

DOI: 10.1021/acsinfecdis.4c00119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Mary Nantongo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University (CWRU), Cleveland, Ohio 44106, United States. Hauptthemen laut MEDLINE: Aminoacyltransferases, Antitubercular Agents, beta-Lactamase Inhibitors, beta-Lactamases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: FIC NIH HHS, NIAID NIH HHS, Fogarty International Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptidoglycan synthesis is an underutilized drug target in Mycobacterium tuberculosis (Mtb). Diazabicyclooctanes (DBOs) are a class of broad-spectrum β-lactamase inhibitors that also inhibit certain peptidoglycan transpeptidases that are important in mycobacterial cell wall synthesis. We evaluated the DBO durlobactam as an inhibitor of BlaC, the Mtb β-lactamase, and multiple Mtb peptidoglycan transpeptidases (PonA1, LdtMt1, LdtMt2, LdtMt3, and LdtMt5). Timed electrospray ionization mass spectrometry (ESI-MS) captured acyl-enzyme complexes with BlaC and all transpeptidases except LdtMt5. Inhibition kinetics demonstrated durlobactam was a potent and efficient DBO inhibitor of BlaC (KI app 9.2 ± 0.9 μM, k2/K 5600 ± 560 M-1 s-1) and similar to clavulanate (KI app 3.3 ± 0.6 μM, k2/K 8400 ± 840 M-1 s-1); however, durlobactam had a lower turnover number (tn = kcat/kinact) than clavulanate (1 and 8, respectively). KI app values with durlobactam and clavulanate were similar for peptidoglycan transpeptidases, but ESI-MS captured durlobactam complexes at more time points. Molecular docking and simulation demonstrated several productive interactions of durlobactam in the active sites of BlaC, PonA1, and LdtMt2. Antibiotic susceptibility testing was conducted on 11 Mtb isolates with amoxicillin, ceftriaxone, meropenem, imipenem, clavulanate, and durlobactam. Durlobactam had a minimum inhibitory concentration (MIC) range of 0.5-16 μg/mL, similar to the ranges for meropenem (1-32 μg/mL) and imipenem (0.5-64 μg/mL). In β-lactam + durlobactam combinations (1:1 mass/volume), MICs were lowered 4- to 64-fold for all isolates except one with meropenem-durlobactam. This work supports further exploration of novel β-lactamase inhibitors that target BlaC and Mtb peptidoglycan transpeptidases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminoacyltransferasesAntitubercular Agentsbeta-Lactamase Inhibitorsbeta-LactamasesMycobacterium tuberculosisAzabicyclo CompoundsBacterial ProteinsKineticsMicrobial Sensitivity TestsMolecular Docking Simulation

Stichwörter der Autor:innen

Mycobacterium tuberculosisdurlobactampeptidoglycantranspeptidasesβ-lactamase inhibitors

Substanzen

AminoacyltransferasesAntitubercular AgentsAzabicyclo CompoundsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-Lactamasespeptidoglycan transpeptidase

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Case Western Reserve University (CWRU), Cleveland, Ohio 44106, United States.
  • Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio 44106, United States.
  • Division of Infectious Diseases, Department of Pediatrics and Division of Infectious Diseases, and Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois 60612, United States.
  • Department of Medicine, Case Western Reserve University (CWRU), Cleveland, Ohio 44106, United States.
  • Medical Service, Veterans Affairs Northeast Ohio Healthcare System (VANEOHS), Cleveland, Ohio 44106, United States.
  • Department of Internal Medicine VIII, Medical Oncology and Pneumology, University of Tübingen, 72076 Tübingen, Germany.

ORCID-Profile: Mary Nantongo, David C Nguyen, Robert A Bonomo

Förderung

  • FIC NIH HHS
  • NIAID NIH HHS
  • Fogarty International Center
  • Division of Microbiology and Infectious Diseases

Zitieren

APA

Nantongo, M., Nguyen, D. C., Bethel, C. R., Taracila, M. A., Li, Q., Dousa, K. M., Shin, E., Kurz, S. G., Nguyen, L., Kreiswirth, B. N., Boom, W. H., Plummer, M. S., & Bonomo, R. A. (2024). Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00119

Vancouver

Nantongo M, Nguyen DC, Bethel CR, Taracila MA, Li Q, Dousa KM, et al. Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00119

BibTeX
@article{Nantongo2024,
  author = {Nantongo, Mary and Nguyen, David C and Bethel, Christopher R and Taracila, Magdalena A and Li, Qing and Dousa, Khalid M and Shin, Eunjeong and Kurz, Sebastian G and Nguyen, Liem and Kreiswirth, Barry N and Boom, W Henry and Plummer, Mark S and Bonomo, Robert A},
  title = {Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis},
  journal = {ACS Infectious Diseases},
  year = {2024},
  doi = {10.1021/acsinfecdis.4c00119}
}
Kostenlos starten →